



(51) International Patent Classification:

C07K 16/28 (2006.01) **C07K 16/30** (2006.01)
C07K 16/18 (2006.01) **A61K 39/395** (2006.01)

(21) International Application Number:

PCT/US2017/021435

(22) International Filing Date:

8 March 2017 (08.03.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/305,092 8 March 2016 (08.03.2016) US

(71) **Applicant:** MAVERICK THERAPEUTICS, INC.
 [US/US]; 3260 B Bayshore Blvd., 1st Floor, Brisbane, CA
 94005 (US).

(72) **Inventors:** BAEUERLE, Patrick; Waldpromenade 18c,
 82131 Gauting (DE). DUBRIDGE, Robert, B.; 825 Holly
 Road, Belmont, CA 94002 (US). WESCHE, Holger; 1080
 Jamestown Avenue, San Francisco, CA 94124 (US). EVN-
 IN, Luke; 768 El Camino Del Mar, San Francisco, CA
 94121 (US). GUENOT, Jeanmarie; 45 Juniper Street, #3,
 San Francisco, CA 94103 (US). PANCHAL, Anand; 2615
 Turk Street, Apt A., San Francisco, CA 94118 (US).
 VINOGRADOVA, Maia; 2079 Ascot Drive, Unit 240,
 Moraga, CA 94556 (US).

(74) **Agents:** MANN, Jeffry S. et al.; Morgan, Lewis & Bock-
 us LLP, One Market Spear Street Tower, San Francisco,
 CA 94105 (US).

(81) **Designated States** (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN,
 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
 RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,
 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a
 patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
 earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: INDUCIBLE BINDING PROTEINS AND METHODS OF USE

FIG. 3



(57) **Abstract:** Provided herein are conditionally activated polypeptide constructs comprising a protease-activated domain binding to CD3, at least one half-life extension domain, and two or more domains binding to one or more target antigens. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such polypeptide constructs. Also disclosed are methods of using the disclosed polypeptide constructs in the prevention, and/or treatment diseases, conditions and disorders.